Eli Lilly maintains lead in obesity drug race as AstraZeneca joins the competition
TL;DR
AstraZeneca has entered the obesity drug market, but Eli Lilly remains the preferred choice for investors.
Topics:businesspharmaceuticals#astrazeneca#competition#eli-lilly#obesity-drug#pharmaceuticals#weight-loss-drug-market
Want the full story? Read the original reporting
Read on CNBC